Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 237218

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237218

License Grant
For the Mutual Research Licenses, the Licensor of Sweden grants, during the term of the Research Program, a co-exclusive, solely with Licensor, world-wide right and license under the Licensor Licensed Technology and Licensor Collaboration Technology, and a co-exclusive, solely with Licensor, world-wide right and sublicense under the ASU Licensed Technology, to conduct the Research Program and to make and use Collaboration Compounds and Covered Products in connection with the Research Program, each in accordance with the terms of this Agreement.

For the Licensee Commercialization License, Limited Partial Conversion to Non-exclusivity, subject to Licensors limited right to manufacture Collaboration Compounds and Covered Products, Licensor grants an exclusive, even as to Licensor, world-wide, royalty-bearing right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses in accordance with the terms of this Agreement, under the ASU Licensed Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.

Licensor grants an exclusive, even as to Licensor, world-wide right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under the Licensor Licensed Technology, the Licensor Collaboration Technology and Licensors interest in the Joint Collaboration Technology to develop, make, have made, use, sell, offer for sale, have sold and export Covered Products.

For the Mutual Ex-Field Licenses, Licensor grants a perpetual, non-exclusive, world-wide right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology and Joint Collaboration Technology for all purposes outside the Field.

License Property
Licensor has been granted a license, with the right to sublicense, certain patent rights and other know-how and technology owned by Arizona State University.

Collaboration Compound shall mean any chemical compound, the composition of matter and/or method of use of which is, or is deemed to be, covered by the ASU Licensed Technology, the Licensor Licensed Technology and/or the OXiGENE Collaboration Technology, and that is the subject of any of the research, development, commercialization and/or marketing activities contemplated by this Agreement. While the Parties intend CA4P to be the initial Collaboration Compound, other compounds may be selected as Collaboration Compounds in addition to, or in lieu of, CA4P.

Combretastatin shall mean any cancer cell growth inhibitory substance derived from the bush willow Combretum caffrum.

CA4P shall mean the chemical compound having the chemical name Combretastatin A4 phosphate.

Field of Use
Field shall mean the prevention, diagnosis, control or treatment of any human or animal disease or condition by the Systemic Use of a Covered Product(s), either as a single agent or in combination with any other therapy. The Field may be modified from time to time.

IPSCIO Record ID: 27630

License Grant
University hereby grants to Licensee an exclusive license in the territory and in the Licensed Field Of Use, which shall include the right to grant sub-licenses, under University collective patent rights in accordance with the specific rights granted below

For University’s Patent Rights I, II, III & IV
University hereby grants to Licensee an exclusive license along with the right to use related Technology and know-how, to develop, have developed, make, have made, market, import, sell, and otherwise use Licensed Products and to practice the licensed methods under University’s Patent Rights I, University’s Patent Rights II, University’s Patent Rights III and University’s Patent Rights IV.

For University's Patent Rights V
University hereby grants to Licensee an option to obtain a license hereunder to each individual compound that is claimed in or covered by University’s Patent Rights V, which license shall be an exclusive license in the Territory and in the Licensed field of Use, including the right to grant sub-licenses, along with the right to use related University Collective Patent Rights, Technology and Know-How, to develop, have developed, make, have made, market, import, sell, and otherwise use related Licensed Products and to practice the related licensed methods for a specified individual compound that is claimed in or covered by University’s Patent Rights V. The Option shall be exercisable on a compound-by-compound basis by written notice given within six-months of the day Licensee receives notification and enabling disclosure from University in accordance with the due-diligence requirements in this Agreement, of each new compound definable by University’s Patent Rights V. Upon exercise of any Option in accordance with the provisions, such compound and related University Patent Rights V, Technology and Know-How shall be licensed to Licensee hereunder as provided above for the consideration set forth herein.

License Property
Certain inventions, generally characterized as a family of drugs known under the name “combretastatins”, collectively referred to as the “TECHNOLOGY”,.

University’s Patent Rights I or University Patent Rights I shall mean patent rights to any subject matter claimed in or covered by any of the following

Under University Case No. 224  
U.S. Patent No. 4,996,237 entitled Combretastatin A-4.
  
Under University Case No. 700
U.S. Patent No. 5,561,122 entitled Combretastatin A-4 Prodrug and any corresponding extensions or foreign applications or patents, if any.

University’s Patent Rights II or University Patent Rights II shall mean patent rights to any subject matter claimed in or covered by any of the following
Under University Case No. 98-014  
PCT Patent Application Serial No. US99/00419, entitled Synthesis of Combretastatin A-4 Prodrugs and Trans-isomers Thereof and any corresponding extensions or foreign applications or patents.

University’s Patent Rights III or University Patent Rights III shall mean patent rights to any subject matter claimed in or covered by any of the following
Under University Case No. 206  
U.S. Patent Nos. 5,409,953 & 5,569,786, entitled Isolation, Structural Elucidation and Synthesis of Novel Antineoplastic Substances Denominated Combretastatins.

Under University Case No. 516  
U.S. Patent No. 4,940,726, entitled Cell Growth Inhibitory Macrocyclic

Lactones Denominated Combretastatin D-1 and Combretastatin D-2 and any corresponding extensions or foreign applications or patents.

University’s Patent Rights IV or University Patent Rights IV shall mean patent rights to any subject matter claimed in or covered by continuing applications deriving from University Patent Rights I or University Patent Rights II or University Patent Rights III including all additions, renewals, divisions, substitutions, continuations and continuation-in-part applications; any patents issuing on said applications or continuing applications including reissues; and any corresponding extensions or foreign applications or patents. For the purposes of this agreement, this definition shall include only patent rights deriving from research conducted using funding from either University internal funds, philanthropic funds or funds from the United States Government. Inventions which are made exclusively under funding from third party for-profit entities or Agencies are excluded. Also excluded are inventions that are made under funding from third party for-profit entities or Agencies in combination with funding sources other than the United States Government.
University’s Patent Rights V or University Patent Rights V shall mean patent rights to any subject matter directed at any compound or group of compounds which are Combretastatins as defined herein and that is not claimed in or covered by University Patent Rights I, University Patent Rights II, University Patent Rights III or University Patent Rights IV. For the purposes of this agreement, this definition shall include only patent rights deriving from research conducted using funding from either Licensee or University internal funds, philanthropic funds or funds from the United States Government. Inventions which are made exclusively under funding from third party for-profit entities or Arizona State Agencies are excluded. Also excluded are inventions that are made under funding from third party for-profit entities or Agencies in combination with funding sources other than the United States Government.

Field of Use
Licensed Field of Use shall mean all uses of Licensed Products or Licensed Methods.

IPSCIO Record ID: 289543

License Grant
The Parties are collaborating in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases as identified below.

Licensor grants under the Licensor Patents,  Licensor Know How and Licensors interest in the Research Technology and Research Technology Patent Rights
—  a non-exclusive, worldwide right and license solely to conduct its Research activities pursuant to this Agreement during the Research Term.
—  Commencing at the expiration of the Research Term and for a period of three years thereafter, a non-exclusive, worldwide right and license to optimize and, in connection with Axys activities under this Agreement, make and use, but not sell, offer for sale or import, Candidate Compounds for use in the Field subject to all other provisions of this Agreement relating to Licensed Products.

License Property
Licensor possess proprietary technology and know-how related to modulation of caspases.

Licensor will initially contribute to the Research, from its libraries of compounds, two 2 compounds – each, a Licensor Compound, identified by the Parties which will be the subject of initial research related activities as provided in the Research Plan.

Apoptosis, or programmed cell death, is a necessary and normal function used by the body to remove damaged cells in an orderly way. Apoptosis is mediated by caspases, a cascade of interconnected enzymes inside the cell, which are normally dormant, but become activated under certain stimuli.

Field of Use
The Parties have entered into a collaboration to discover and develop anti-cancer agents that induce apoptosis (programmed cell death).

IPSCIO Record ID: 289168

License Grant
The Parties will collaborate in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases.

Licensor grants Licensee under the Licensor Patents, Licensor Know-How and Licensors interest in the Research Technology and the Research Technology Patent Rights
— a non-exclusive, worldwide, right and license, without the right to sub license, solely to conduct its Research activities pursuant to this Agreement during the Research Term; and
— if Licensee exercises its License Option, commencing at the expiration of the Research Term and for a period of 3 years thereafter, a non-exclusive, worldwide,  right and license, with the right to sub license solely to optimize, and, in connection with Licensees activities under this Agreement, make and use, but not sell, offer for sale or import, solely in connection with such optimization, Released Compounds for use in the Field.

Licensor grants Licensee an exclusive option during, the 4 month period following each decision by Licensor not to advance any particular Candidate Compound as either a Clinical Development Compound or Back-Up Compound, to obtain an exclusive, including with regard to Licensor, world-wide, right and license, with the right to sublicense, under the Licensor Patents and Licensor Know-How solely to conduct development on, and to make, have made and use for such purpose, any such Released Compounds for use in the Field, and to make, have made, import, use, sell and offer for sale pharmaceutical products containing or comprising any such Released Compounds in any formulation, each, a Released Product, for use in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, diseases within the field of cancer.

Licensed Product means any product, including any formulation thereof, containing or comprising a Clinical Development Compound for use within the Field.

Licensor will initially provide Licensee with approximately [0.5 micromoles] each of approximately four hundred thousand (400,000) compounds, each an Licensor Compound in a 384 well format.

Field of Use
Field means any and all uses for the prevention or treatment of human disease. Licensee and its Affiliates possess proprietary technology and know-how related to modulation of caspases.

Caspases are a family of protease enzymes playing essential roles in programmed cell death.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.